- Home
- SILO
SILO
Silo Pharma Inc.
as of 03-09-2026 3:58pm EST
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 4.6M | IPO Year: | 2011 |
| Target Price: | N/A | AVG Volume (30 days): | 425.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.50 | EPS Growth: | 0.83 |
| 52 Week Low/High: | $0.22 - $1.44 | Next Earning Date: | N/A |
| Revenue: | $72,102 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1.86% | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.66 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of Silo Pharma Inc. (SILO)
Chief Executive Officer
Avg Cost/Share
$0.42
Shares
5,000
Total Value
$2,075.00
Owned After
214,432
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Weisblum Eric | SILO | Chief Executive Officer | Dec 15, 2025 | Buy | $0.42 | 5,000 | $2,075.00 | 214,432 |
Compare SILO vs Leading Stocks
See how SILO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SILO Silo Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.